studies

794A AASLD ABSTRACTS HEPATOLOGY, October, 2015
and 8( 22.9) received everolimus. 31(24 genotype 1a, 9 genotype
1b) patients completed a 24 week course of therapy,
the remaining 4 patients completed an 8 (genotype 1a),12
(genotype 1a),15 (genotype 1b) and 16 (genotype 1a) weeks
of therapy individually. Side effects were reported in six of the
patients and they included fatigue, somnolence, headache,
anemia, photosensitivity and weight gain. In genotype 1a,
4(16%) patients had RVR, 35 (100%) patients had ETR and
SVR at 4 and 12 weeks. In genotype 1b, 2 (20%) patients had
RVR, 8(80%) patients had ETR and SVR at 4 and 12 weeks.
One of the non responders discontinued treatment before completion
due to decompensation. Overall response rate for genotype
1a and 1b was 94.3%. No patient required adjustment in
IS and no episodes of rejection were documented during treatment.
Conclusion: In patients with recurrent genotype 1 (a or b)
hepatitis C after LT, the combination of once daily sofosbuvir
and simeprevir is generally well tolerated with very high overall
response rates. Discontinuation of treatment only occurred in
two patients due to decompensation of cirrhosis. There were
no interactions that required adjustments in IS.
Disclosures:
Nikolaos Pyrsopoulos - Advisory Committees or Review Panels: GILEAD, BMS,
ABBVIE, VITAL THERAPIES, Quest; Grant/Research Support: ABBVIE
The following authors have nothing to disclose: Nneoma O. Okoronkwo, George
Protopopas, Kiran V. Rao, Vivek A. Lingiah, Maliha Ahmad, Lizza Bojito-Marrero,
Kathleen Ruping, Raj Edula
was very common in both groups (48%). RBV dose reduction
occurred in 8 Asians (26%) and 20 non-Asians (19%). SAE
occurred in 5 non-Asian and all were unrelated to treatment.
Conclusion: Asian and non-Asian CHC-1 patients treated with
SMV+SOF showed similar high treatment response and good
tolerability, despite high rates of advanced disease and prior
treatment failure. Anemia and fatigue were common in both
Asians and non-Asians treated with SOF+RBV.
1182
Similar Tolerability and Effectiveness with SMV+SOF
Therapy in Asians and Non-Asians with Chronic Hepatitis
C Genotype 1 (CHC-1) but Anemia and Fatigue were
Common with SOF+RBV in Both Groups
Christine Y. Chang 1 , Nghia H. Nguyen 2,1 , Changqing Zhao 1,3 ,
Glen A. Lutchman 1 , Aijaz Ahmed 1 , Tami Daugherty 1 , Gabriel
Garcia 1 , Radhka Kumari 1 , W. Ray Kim 1 , Huy N. Trinh 4 , Vinh D.
Vu 1 , Winston Ku 1 , My T. Nguyen 4 , Andrew Huynh 4 , Mindie H.
Nguyen 1 ; 1 Division of Gastroenterology and Hepatology, Stanford
University Medical Center, Palo Alto, CA; 2 Department of
Medicine, University of California, San Diego, San Diego, CA;
3 Institute of Liver Disease, Shugang Hospital, Department of Cirrhosis,
Shanghai, China; 4 San Jose Gastroenterology, San Jose, CA
Purpose: Asian CHC-1 patients can have much higher SVR
with IFN-based therapy but more likely to develop anemia than
non-Asians. Our goal is to investigate for possible ethnic-related
differences in SVR12 or tolerability with DAA-based therapy.
Methods: We evaluated outcomes of DAA-based therapy
(SOF+SMV, SOF+RBV, or SOF+LDV±RBV for 8-24) in 401
patients (330 non-Asians and 71 Asians) seen at 2 US centers
from 12/2013-12/2014. Results: Asians were mostly Vietnamese
(38%) and Chinese (24%). Non-Asians were mostly
Caucasian (62%) and Hispanic (26%). Compared to non-
Asians, Asians were older (mean age: 63±11 vs. 60±9 years,
p=0.004) with lower BMI (26±7 vs. 28±5 kg/m 2 , p=0.01)
and more likely to have HCV-2 (30% vs. 19%) or HCV-6 (8%
vs. 0%), and less likely to have HCV-1 (54% vs. 68%) or 4 (0%
vs. 1%), p